These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28436391)

  • 1. Prediction of Conversion to Alzheimer's Disease with Longitudinal Measures and Time-To-Event Data.
    Li K; Chan W; Doody RS; Quinn J; Luo S;
    J Alzheimers Dis; 2017; 58(2):361-371. PubMed ID: 28436391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.
    Da X; Toledo JB; Zee J; Wolk DA; Xie SX; Ou Y; Shacklett A; Parmpi P; Shaw L; Trojanowski JQ; Davatzikos C;
    Neuroimage Clin; 2014; 4():164-73. PubMed ID: 24371799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Derivation of a new ADAS-cog composite using tree-based multivariate analysis: prediction of conversion from mild cognitive impairment to Alzheimer disease.
    Llano DA; Laforet G; Devanarayan V;
    Alzheimer Dis Assoc Disord; 2011; 25(1):73-84. PubMed ID: 20847637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Alzheimer's disease based on survival data and longitudinally measured performance on cognitive and functional scales.
    Wu Y; Zhang X; He Y; Cui J; Ge X; Han H; Luo Y; Liu L; Wang X; Yu H;
    Psychiatry Res; 2020 Sep; 291():113201. PubMed ID: 32559670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A point-based tool to predict conversion from mild cognitive impairment to probable Alzheimer's disease.
    Barnes DE; Cenzer IS; Yaffe K; Ritchie CS; Lee SJ;
    Alzheimers Dement; 2014 Nov; 10(6):646-55. PubMed ID: 24495339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information.
    Steenland K; Zhao L; John SE; Goldstein FC; Levey A; Alvaro A;
    J Alzheimers Dis; 2018; 63(4):1383-1393. PubMed ID: 29843232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI.
    Landau SM; Harvey D; Madison CM; Koeppe RA; Reiman EM; Foster NL; Weiner MW; Jagust WJ;
    Neurobiol Aging; 2011 Jul; 32(7):1207-18. PubMed ID: 19660834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Progression From Mild Cognitive Impairment to Alzheimer's Disease Using Autoregressive Modelling of Longitudinal and Multimodal Biomarkers.
    Minhas S; Khanum A; Riaz F; Khan SA; Alvi A
    IEEE J Biomed Health Inform; 2018 May; 22(3):818-825. PubMed ID: 28534796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research on predicting the risk of mild cognitive impairment in the elderly based on the joint model].
    Xu J; Yuan MQ; Fang Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Feb; 43(2):269-276. PubMed ID: 35184495
    [No Abstract]   [Full Text] [Related]  

  • 11. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
    Dukart J; Sambataro F; Bertolino A
    J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers.
    Zhang D; Shen D;
    PLoS One; 2012; 7(3):e33182. PubMed ID: 22457741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG-PET and CSF biomarker accuracy in prediction of conversion to different dementias in a large multicentre MCI cohort.
    Caminiti SP; Ballarini T; Sala A; Cerami C; Presotto L; Santangelo R; Fallanca F; Vanoli EG; Gianolli L; Iannaccone S; Magnani G; Perani D;
    Neuroimage Clin; 2018; 18():167-177. PubMed ID: 29387532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects.
    Moradi E; Pepe A; Gaser C; Huttunen H; Tohka J;
    Neuroimage; 2015 Jan; 104():398-412. PubMed ID: 25312773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing predictors of conversion and decline in mild cognitive impairment.
    Landau SM; Harvey D; Madison CM; Reiman EM; Foster NL; Aisen PS; Petersen RC; Shaw LM; Trojanowski JQ; Jack CR; Weiner MW; Jagust WJ;
    Neurology; 2010 Jul; 75(3):230-8. PubMed ID: 20592257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
    Podhorna J; Krahnke T; Shear M; Harrison JE;
    Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Neuropsychological Correlates of Brain Perfusion and Gray Matter Volume in Alzheimer's Disease.
    Tai H; Hirano S; Sakurai T; Nakano Y; Ishikawa A; Kojima K; Li H; Shimada H; Kashiwado K; Mukai H; Horikoshi T; Sugiyama A; Uno T; Kuwabara S
    J Alzheimers Dis; 2020; 78(4):1639-1652. PubMed ID: 33185599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker Matrix to Track Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease.
    Marizzoni M; Ferrari C; Macis A; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Pizzini F; Rossini PM; Salvatore M; Schönknecht P; Soricelli A; Del Percio C; Hensch T; Hegerl U; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):49-58. PubMed ID: 30958351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort.
    Risacher SL; Saykin AJ; West JD; Shen L; Firpi HA; McDonald BC;
    Curr Alzheimer Res; 2009 Aug; 6(4):347-61. PubMed ID: 19689234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.